News

Deal Announcements

Tranzyme Clears $20 Million In Development Funding

Friday, November 2, 2007 5:00:00 AM PDT | VentureDeal Staff
DURHAM, NC -- Biopharmaceutical company Tranzyme Pharma said that it has completed a new round of venture capital financing, receiving $20 million.

Tranzyme is developing orally bioavailable, small molecule therapeutics for the treatment of gastrointestinal (GI) diseases.

Investors who lead the round were H.I.G. Ventures, Thomas, McNerny & Partners, Quaker BioVentures and BDC Venture Capital.  The company said it will use the proceeds to continue development of its GI drugs.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1